Search Saint Luke's

Dr. Timothy Bateman spoke with Cardiovascular Business about his group's findings and what it is like to work with flurpiridaz.

Cardiovascular Business spoke with Dr. Timothy Bateman about his views on SPECT advances and its longevity in the coming years.

Saint Luke’s receives $10 million endowment to establish first institute dedicated to studying unique aspects of heart conditions in women.

Rehospitalization after aortic valve replacement (AVR) is associated with an increased risk of patient mortality, according to new research.

Percutaneous coronary intervention is associated with significant short-term improvements in high-risk patients with complex coronary artery disease who are ineligible for coronary artery bypass grafting, according to a new analysis.

The new Saint Luke’s Muriel I. Kauffman Institute for Women’s Cardiovascular Research is the first of its kind dedicated to studying unique aspects of heart conditions in women.

Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.

In 2021, Saint Luke’s launched its heart team-led Wound Transition Program, which went on to surpass national goals and cut PAD amputation rates in half.

TAVR in asymptomatic and minimally symptomatic patients is associated with a high survival rate, but relatively minor improvements, according to new research.

Get With The Guidelines put the expertise of the American Heart Association and American Stroke Association to work for hospitals nationwide, helping ensure patient care is aligned with the latest evidence- and research-based guidelines.